Bayer collaborates with Gubra to unleash peptide potential

A drug candidate developed by Danish firm Gubra has caught Bayer's eye, so the parties are now collaborating to bring it to market. Bayer will pay millions of dollars in milestone payments, if the candidate performs.

Photo: Muusfoto / Gubra / PR

Bayer, which is one of the world's largest pharmaceutical companies, has become the latest partner of contract research and biotech company Gubra.

On Monday, the biotech company reported that it had entered into a sales and licensing agreement with Bayer, which could secure it up to USD 253m in the form of an upfront payment and future milestone payments, provided a number of development and commercial goals are met.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs